表决结果：3 票同意，0 票弃权，0 票反对，议案获得通过。 证券代码：002550 证券简称：千红制药 公告编号：2024-037 常州千红生化制药股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届 监事会第四次会议通知于 2024 年 10 月 8 日通过电子邮件方式发出，本次会议于 2024 年 10 月 18 日在公司会议室召开。本次会议应出席监事 3 人，实际出席监 事 3 人。本次会议由监事会主席刘军先生召集并主持。本次会议的召开符合《公 司法》等法律法规和《公司章程》的有关规定，本次会议所形成的有关决议合法 有效。 本次监事会会议形成决议如下： 一、审议并通过了《公司 2024 年第三季度报告的议案》 经审核，监事会认为董事会编制和审核常州千红生化制药股份有限公司 2024 年第三季度报告的程序符合法律、行政法规和中国证监会的规定，报告内 容真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 《常州 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-039 常州千红生化制药股份有限公司 关于签署《关于常州方圆制药有限公司之重整投资协议》 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、协议签署概况 1、基本情况 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）于 2024 年 10 月 17 日与常州方圆制药有限公司破产管理人签订了《关于常州方圆制药 有限公司之重整投资协议》（以下简称："投资协议"或"本协议"），公司参与常 州方圆制药有限公司（以下简称"方圆制药"）的破产重整，拟通过出资 39,000 万元收购方圆制药全部的股权以取得与该股权对应的重整资产。 2、合同签订已履行的审议决策程序 公司于 2024 年 10 月 17 日召开第六届董事会第六次会议、第六届监事会第 四次会议，审议通过了《关于签署<参与常州方圆制药有限公司重整投资协议>的 议案》，根据《深圳证券交易所股票上市规则》、《公司章程》等相关规定，本次 投资事项在董事会审批权限内，无需提交公司股东大会审议。 3、本次投资项目不构成关联交易，也不构成《 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-040 公司本次续聘会计师事务所事项符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会[2023]4 号）的规定。 现将相关事项公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息。公证天业会计师事务所（特殊普通合伙）（以下简称"公证天 业"）成立于 1982 年，2013 年 9 月转制为特殊普通合伙性质会计师事务所，注 册地址为无锡市太湖新城嘉业财富中心 5-1001 室。公证天业已取得江苏省财政 厅颁发的会计师事务所执业证书，是我国较早从事证券业务的会计师事务所之一， 长期从事证券服务业务。2020 年 11 月，财政部、证监会公布《从事证券服务 业务会计师事务所备案名单及基本信息》，公证天业成为从事证券服务业务首批 备案的会计师事务所。 常州千红生化制药股份有限公司 关于拟续聘2024年度会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司(以下简称"公司")于 2024 年 10 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-041 常州千红生化制药股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：本次股东大会是常州千红生化制药股份有限公司（以 下简称"千红制药"或"公司"）2024 年第二次临时股东大会。 （二）股东大会的召集人：公司董事会。2024 年 10 月 17 日，公司第六届 董事会第六次会议审议通过了《关于召开 2024 年第二次临时股东大会通知的议 案》。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程等的规定。 （四）会议召开的日期、时间： 1. 现场会议召开时间：2024 年 11 月 5 日（周二）下午 15:00 2. 网络投票时间：2024 年 11 月 5 日 通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 11 月 5 日 上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 通过深圳证 ...

Financial Performance - The company's revenue for Q3 2024 was ¥352,007,088.55, a decrease of 13.97% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥126,792,812.09, an increase of 60.84% year-on-year[2] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥48,778,115.49, down 9.80% from the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.1015, reflecting a 64.24% increase compared to the same period last year[2] - Total operating revenue for the period was CNY 1,207,602,942.05, a decrease of 17.6% compared to CNY 1,465,941,311.21 in the previous period[13] - Net profit for the period was CNY 298,597,921.90, an increase of 59.1% compared to CNY 187,652,324.30 in the previous period[14] - Earnings per share (EPS) for the period was CNY 0.2471, up from CNY 0.1549 in the previous period[15] - The company’s total comprehensive income for the period was CNY 298,737,624.85, compared to CNY 186,086,657.27 in the previous period[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,762,272,162.00, a slight decrease of 0.14% from the end of the previous year[2] - The total assets amounted to CNY 2,762,272,162.00 and equity amounted to CNY 2,484,899,948.42 respectively[12] - The total liabilities decreased from ¥292,172,947.64 to ¥277,372,213.58, a decline of approximately 5.1%[11] - The company’s total liabilities and equity decreased slightly from CNY 2,766,081,444.15 to CNY 2,762,272,162.00[12] Cash Flow - Operating cash inflow for the current period was CNY 1,303,233,031.89, a decrease of 32.8% from CNY 1,939,647,154.95 in the previous period[16] - Net cash flow from operating activities increased to CNY 450,750,025.74, up 15.2% from CNY 391,002,276.99 year-over-year[16] - Cash outflow from investing activities was CNY 303,959,223.80, a decrease of 8.0% compared to CNY 329,978,441.76 in the previous period[17] - Net cash flow from investing activities improved to -CNY 58,777,577.01, an improvement of 45.8% from -CNY 108,039,608.48 year-over-year[17] - Cash inflow from financing activities decreased significantly to CNY 3,000,000.00 from CNY 442,500,000.00 in the previous period[17] - Net cash flow from financing activities was -CNY 325,099,885.02, worsening from -CNY 226,310,659.25 year-over-year[17] - The ending balance of cash and cash equivalents increased to CNY 637,459,832.53, up from CNY 464,690,328.84 in the previous period[17] Expenses and Costs - The company's gross profit margin improved, contributing to a net profit increase due to the recovery of previously provisioned bad debts[5] - Research and development expenses increased compared to the previous year, impacting the net profit excluding non-recurring items[5] - The company's development expenditures increased to ¥99,660,827.47 from ¥70,162,324.03, representing a growth of about 42.3%[11] - Total operating costs decreased to CNY 957,440,753.08, down 26.4% from CNY 1,300,459,887.27 in the previous period[13] - Cash paid for employee compensation decreased slightly to CNY 159,473,556.56 from CNY 165,156,895.07 in the previous period[16] Inventory and Receivables - The company reported a 63.56% decrease in notes receivable at the end of the reporting period, attributed to increased payments of bank acceptance bills[5] - Inventory decreased by 35.09% compared to the beginning of the year, mainly due to a drop in the price of key raw materials[5] - Inventory decreased significantly from ¥602,010,484.51 to ¥390,770,971.42, a reduction of approximately 35.1%[10] - Accounts receivable rose to ¥270,788,117.63 from ¥225,031,849.78, indicating an increase of about 20.3%[10]

Financial Performance - The net profit attributable to shareholders for the first three quarters of 2024 is expected to be 309.58 million yuan, representing a year-on-year increase of 56.47% compared to 197.86 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is expected to be 215.10 million yuan, an increase of 29.74% from 165.79 million yuan in the previous year [2]. - The basic earnings per share for the first three quarters is expected to be 0.25 yuan, up from 0.15 yuan in the same period last year [2]. - For the third quarter of 2024, the net profit attributable to shareholders is expected to be 126.79 million yuan, a year-on-year increase of 60.84% compared to 78.83 million yuan [3]. - The net profit after deducting non-recurring gains and losses for the third quarter is expected to be 35.64 million yuan, a decrease of 34.09% from 54.08 million yuan in the previous year [3]. - The basic earnings per share for the third quarter is expected to be 0.10 yuan, compared to 0.06 yuan in the same period last year [3]. Non-Recurring Gains and Losses - The company received a settlement payment of 85 million yuan related to a dispute with Jianyuan Trust, contributing to the non-recurring gains and losses of 94.48 million yuan during the reporting period [5]. Profitability and Expenses - The gross profit margin has continued to improve compared to the same period last year, while the sales expense ratio has gradually decreased, leading to sustained growth in net profit [5]. Caution and Auditing - The performance forecast has not been audited by the accounting firm, and specific financial data will be confirmed in the third-quarter report [4]. - Investors are advised to exercise caution as the performance forecast is based on preliminary estimates by the company's finance department [5].

本次董事会会议形成决议如下： 一、审议并通过了《关于公司与建元信托股份有限公司签署和解协议的议 案》 证券代码：002550 证券简称：千红制药 公告编号：2024-033 常州千红生化制药股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届 董事会第五次会议通知于 2024 年 9 月 24 日通过邮件方式送达，会议于 2024 年 9 月 30 日在公司会议室召开，会议应出席董事 9 人，实际出席董事 9 人。会议 由董事长王耀方先生召集并主持。本次会议的通知、召开以及董事出席人数和表 决人数符合《公司法》等法律法规和本公司《公司章程》的有关规定，本次会议 所形成的有关决议合法、有效。 常州千红生化制药股份有限公司 董事会 2024 年 10 月 9 日 2024 年 9 月 30 日，经双方友好协商，公司与建元信托股份有限公司就锐赢 64 号信托计划理财产品纠纷案（案号（2020）沪 74 民初 5 号）达成和解并签署 了《和解协议》。该协议签署当 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-034 常州千红生化制药股份有限公司 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）2018 年 购买了安信锐赢 64 号·流动资金贷款集合资金信托计划（以下简称"锐赢 64 号 信托计划"）理财产品，到期时间为 2019 年 8 月 15 日。自 2019 年 8 月起，该笔 理财产品出现逾期未兑付，逾期本金 17,000 万元。公司就锐赢 64 号信托计划项 下与建元信托股份有限公司（以下简称"建元信托"）的受益权转让协议纠纷向 上海金融法院提起诉讼，案号为（2020）沪 74 民初 5 号，法院受理时的涉诉金 额为 19,831.72 万元。具体情况详见公司披露的《2018 年年度报告》、《2019 年年 度报告》、《2020 年年度报告》、《2021 年年度报告》、《2022 年年度报告》、《2023 年年度报告》与《诉讼公告》（公告编号：2020-001）。 二、本次诉讼的进展情况 2024年9月30日，经双方友好协商，公司与建元信托股份有限公司达成和解 1. 案件所处的诉讼阶段：1 宗案件已和解且已撤诉。 2. 上市公司 ...

Investment Rating - The investment rating for the company is maintained at "Accumulate" [4][3]. Core Insights - In H1 2024, the company achieved a rapid profit growth with a significant increase in gross margin, reporting a revenue of 856 million yuan, down 19.04% year-on-year, and a net profit attributable to shareholders of 183 million yuan, up 53.57% year-on-year [1]. - The raw material drug segment saw a notable gross margin increase to 33.70%, up 20.31 percentage points year-on-year, despite a revenue decline of 41.34% to 269 million yuan [1]. - The formulation segment's revenue was 584 million yuan, down 1.49% year-on-year, with a gross margin of 61.36%, down 1.99 percentage points [1]. - The company has two innovative drugs in phase II clinical trials and two more expected to enter phase II soon, with positive safety and efficacy results reported [2]. Financial Performance Summary - The company forecasts revenues of 1.711 billion yuan, 2.202 billion yuan, and 2.507 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 316 million yuan, 356 million yuan, and 429 million yuan for the same years [3][4]. - The gross margin is projected to improve to 53.07% in 2024, with a net profit margin of 18.47% [7]. - The company’s total assets are estimated to be 2.748 billion yuan in 2024, with a debt ratio of 8.65% [7].

公 司 研 究 [Table_Reportdate] 2024年08月19日 医 药 生 物 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn 联系人 付婷 futing@longone.com.cn | --- | --- | --- | |------------------------------------|------------|-------| | | | | | | | | | 数据日期 Table_cominfo] 收盘价 | 2024/08/16 | | | 总股本 万股 | 5.65 | | | ( ) | 127,980 | | | 流通 A 股 /B 股 ( 万股 ) | 91,023/0 | | | 资产负债率 (%) | 10.32% | | | 市净率 ( 倍 ) | 3.07 | | | 净资产收益率 ( 加权 ) | 7.60 | | | 12 个月内最高 ...